Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations (MMR)
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age.
Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Listed as NCT01777529, this PHASE4 trial focuses on Measles and Mumps and remains completed. Sponsored by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz), it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)Study Design
This is a clinical trial Phase IV, randomized, single-blind, with two arms:
* MMR (TV) combined measles, mumps and rubella vaccine produced in Bio-Manguinhos, applied to healthy children 12 to 23 months. Multidose presentation, only from one batch.
* MMR (GSK-TV), produced by GlaxoSmithKline, the same age. Monodose presentation, only from one batch.
Locations of the study
* CMS Heitor Beltrão - Tijuca
* CMS Milton Fontess Magarão - Engenho de Dentro
* CMS Waldyr Franco - Bangu
Study Design
This is a clinical trial Phase IV, randomized, single-blind, with two arms:
* MMR (TV) combined measles, mumps and rubella vaccine produced in Bio-Manguinhos, applied to healthy children 12 to 23 months. Multidose presentation, only from one batch. * MMR (GSK-TV), produced by GlaxoSmithKline, the same age. Monodose presentation, only from one batch.
Locations of the study
* CMS Heitor Beltrão - Tijuca * CMS Milton Fontess Magarão - Engenho de Dentro * CMS Waldyr Franco - Bangu
Status Flow
Change History
6 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
For direct contact, visit the study record on ClinicalTrials.gov .